30 closest matches · ranked by relevance
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Anal Chlamydia Infection
Primary: The Proportion of Subjects With Microbiologic Cure (Negative Rectal CT NAAT Result) at Day 29 — 0.74; 1.00 proportion of participants — p=<0.001
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
Anal Cancer
Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants
Fecal Incontinence
Primary: Primary Effectiveness Endpoint — 75.9 percentage of treatment responders
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Trachoma
Primary: Solicited Local Injection Site Reactions — 2; 8; 3; 9 Participants — p=1
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Anal Cancer · HIV Infection · Human Papilloma Virus Infection
Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants
HIV Infections
Primary: Mucosal Toxicity Using Histopathology — 0.6; 0.5; 4.2 units on a scale — p=<.05
High Grade Anal Canal Squamous Intraepithelial Neoplasia · Human Immunodeficiency Virus
Primary: Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life…
Urogential Chlamydia Trachomatis Infection
Primary: Microbiological Cure Rate — 94.9; 94.6 percentage of participants cured
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
Urethritis
Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
Chlamydia Trachomatis Infection · Neonatal Infection · Preterm Birth
Primary: Number of Women Diagnosed With C. Trachomatis and N. Gonorrhoeae Infection at Post-delivery — 2; 23 Participants
Chlamydia Trachomatis Infection
Primary: Urogenital CT Infection — 14; 28 Participants — p=0.0256
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Fissure in Ano · Pain
Primary: Change From Baseline in Pain Intensity at Days 14-18 — -40.4; -34.9 Units on a scale
Chlamydial Infection
Primary: Proportion of Participants Experiencing Treatment Failure After Treatment With Azithromycin for Uncomplicated Chlamydia Trachomatis (CT) in Males With and Without…
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Fecal Incontinence
Primary: Change in Anal Incontinence as Measured on the St. Mark's Score — 4.3; 4.5; 3.6; 4.1 units on a scale
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants